Website Changes
05/01/2013
May is Brain Tumor Awareness Month! New Fundraising opportunities!
05/01/2013
Save the Date: Diagnosis Brain Tumor - You Are NOT Alone V: JFK Medical Center, October 5, 2013
04/28/2013
Online discussion group for the
Novocure TTF system
04/28/2013
Oregon Neurosurgeon Dr. Jefferson Chen Uses New Approach for Treatment of Brain Tumors and Blood Clots
04/24/2013
It’s time to Register for Camp Jinka!
04/24/2013
7TH ANNUAL LONG BEACH FIREFIGHTERS AND TOM ATKINSON MEMORIAL EVENT BENEFITING BRAIN CANCER RESEARCH AT UCLA SET FOR JUNE 6TH AT GASLAMP IN LONG BEACH
04/21/2013
IBTA E NEWS APRIL 2013
04/20/2013
Final arrangements: Hitting the digital dead man`s switch
04/19/2013
NW Bio Announces That Another Brain Cancer Patient From Phase I/II DCVax(R)-L Trials Has Surpassed Ten-Year Cancer-Free Survival
04/19/2013
National Walk To End Brain Tumors
04/17/2013
The impact of improved treatment strategies on overall survival in glioblastoma patients.
04/12/2013
Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience.
04/12/2013
J Neurooncol. 2013 Apr 6. [Epub ahead of print]
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.
Santoni M, Scoccianti S, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Iacovelli R, Burattini L, Berardi R, Cascinu S.
Clinica di Oncologia Medica, AOU "Ospedali Riuniti", Università Politecnica delle Marche, via Tronto 10/A, 60100, Ancona, Italy, mattymo@alice.it.
Abstract
Fotemustine (FTM) is a common treatment option for glioblastoma patients refractory to temozolomide (TMZ). Although elderly patients represent a large component of glioblastoma population, the feasibility and the efficacy of second-line FTM are not available in those patients.We retrospectively analyzed the records of glioblastoma patients older than 65 years, receiving FTM at a dose of 70-100 mg/m2 of FTM every week for 3 consecutive weeks (induction phase) and then every 3 weeks (70-100 mg/m2), as second-line treatment.Between January 2004 and December 2011, 65 glioblastoma patients (median age, 70 years; range, 65-79 years) were eligible for this analysis. Sixty-five patients received a total of 364 FTM cycles, with a median of 4 cycles for each patient. After induction, we observed 1 complete response (1.5 %), 12 partial responses (18.5 %), 18 stable diseases (27.7 %), and 34 patients` progressions (47.7 %). Disease control rate was 43.1 %. Median survival from the beginning of FTM therapy was 7.1 months, while the median progression-free survival was 4.2 months, and the 6-months progression free survival rate was 35.4 %. The most relevant grade 3-4 toxicity events were thrombocytopenia (15.3 %) and neutropenia (9.2 %). In the univariate and multivariate analysis, time from radiotherapy to FTM, number of TMZ and FTM cycles and disease control resulted independent prognostic factors.This study showed that FTM is a valuable therapeutic option for elderly glioblastoma patients, with a safe toxicity profile.
PMID: 23564276 [PubMed - as supplied by publisher]
04/12/2013
Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma.
04/12/2013
UCLA 13th Annual Brain Tumor Conference - For patients and families
04/12/2013
Ninth Surviving Brain Tumors Awareness Event—Cleveland
04/10/2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
04/10/2013
Radiation therapy new cancer cure
04/08/2013
Feds to cut Medicare payments for cancer-fighting Gamma Knife, thanks to Congress
03/31/2013
National Walk To End Brain Tumors - New Locations!
03/29/2013
Cancer Drug That Shrinks All Tumors Set To Begin Human Clinical Trials
03/27/2013
Musella Foundation Copay assistance program is now closed
03/27/2013
Device tested to treat aggressive brain tumors
03/26/2013
IFRT offers viable alternative to WBRT
03/24/2013
NY Yankees Fundraiser June 21!
which delivers brain tumor news and additions
to the website via RSS.